IPST vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 13, 2026

IPST

46.8
AI Score
VS
HIVE Wins

HIVE

48.3
AI Score

Investment Advisor Scores

IPST

47score
Recommendation
HOLD

HIVE

48score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric IPST HIVE Winner
Revenue 1.71M 79.12M HIVE
Net Income -66.74M -142.91M IPST
Gross Margin 68.3% -37.3% IPST
Net Margin -3898.1% -180.6% HIVE
ROE -205.9% -33.8% HIVE
ROA -156.1% -15.5% HIVE
Total Assets 42.77M 924.64M HIVE
Cash 92,703 208.04M HIVE
Current Ratio 0.43 1.96 HIVE

Relative Price Performance (Last 90 Days)

IPST 1M: +84.1% · 3M: +8.2% HIVE 1M: +10.6% · 3M: -20.1%

Current Technical Phase

IPST

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.6 · Price: $3.70

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.8 · Price: $3.03

Fundamentals Snapshot

Metric IPST HIVE
Market Cap
Forward P/E 0.7 -5.9
Trailing P/E
Revenue (TTM)
Revenue Growth 0.6% 0.7%
Gross Margin 0.6% 0.4%
Operating Margin -1.1% -0.6%
EPS -310.76 -1.33
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.